{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:46:08Z","timestamp":1740185168993,"version":"3.37.3"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR003017"],"award-info":[{"award-number":["UL1TR003017"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020097","name":"Foundation for Opioid Response Efforts","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020097","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100025438","name":"Forest Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100025438","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["1R01DA047347"],"award-info":[{"award-number":["1R01DA047347"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jsatjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Use and Addiction Treatment"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.josat.2024.209476","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T06:39:19Z","timestamp":1723012759000},"page":"209476","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Methadone treatment utilization and overdose trends among Medicaid beneficiaries in New Jersey before and during the COVID-19 pandemic"],"prefix":"10.1016","volume":"167","author":[{"given":"James","family":"Lloyd","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Treitler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamey J.","family":"Lister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Molly","family":"Nowels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Crystal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.josat.2024.209476_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108552","article-title":"Changes in methadone take-home dosing before and after COVID-19","volume":"133","author":"Amram","year":"2022","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"4","key":"10.1016\/j.josat.2024.209476_bb0010","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1080\/00952990.2021.1903023","article-title":"Common themes in early state policy responses to substance use disorder treatment during COVID-19","volume":"47","author":"Andraka-Christou","year":"2021","journal-title":"The American Journal of Drug and Alcohol Abuse."},{"issue":"10","key":"10.1016\/j.josat.2024.209476_bb0015","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1111\/add.14643","article-title":"Understanding and using time series analyses in addiction research","volume":"114","author":"Beard","year":"2019","journal-title":"Addiction"},{"key":"10.1016\/j.josat.2024.209476_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108449","article-title":"Changes in methadone program practices and fatal methadone overdose rates in Connecticut during COVID-19","volume":"131","author":"Brothers","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2024.209476_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108393","article-title":"The new services that opioid treatment programs have adopted in response to COVID-19","volume":"130","author":"Cantor","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"author":"Centers for Disease Control and Prevention, National Center for Health Statistics","key":"10.1016\/j.josat.2024.209476_bb0030"},{"year":"2020","series-title":"COVID-19 and opioid treatment program guidance","author":"Division of Mental Health and Addiction Services","key":"10.1016\/j.josat.2024.209476_bb0035"},{"author":"Executive Order No. 103","key":"10.1016\/j.josat.2024.209476_bb0040"},{"author":"Federal Opioid Treatment Standards","key":"10.1016\/j.josat.2024.209476_bb0045"},{"key":"10.1016\/j.josat.2024.209476_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108276","article-title":"Take-home dosing experiences among persons receiving methadone maintenance treatment during COVID-19","volume":"123","author":"Figgatt","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2024.209476_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.109049","article-title":"The impact of COVID-19 on opioid treatment programs in the United States","volume":"228","author":"Goldsamt","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"issue":"9","key":"10.1016\/j.josat.2024.209476_bb0060","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1001\/jama.2022.1271","article-title":"Association between increased dispensing of opioid agonist therapy take-home doses and opioid overdose and treatment interruption and discontinuation","volume":"327","author":"Gomes","year":"2022","journal-title":"Journal of the American Medical Association"},{"issue":"5","key":"10.1016\/j.josat.2024.209476_bb0065","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/pds.4157","article-title":"Assessing the accuracy of opioid overdose and poisoning codes in diagnostic information from electronic health records, claims data, and death records","volume":"26","author":"Green","year":"2017","journal-title":"Pharmacoepidemiology and Drug Safety"},{"key":"10.1016\/j.josat.2024.209476_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2022.108801","article-title":"Treatment retention, return to use, and recovery support following COVID-19 relaxation of methadone take-home dosing in two rural opioid treatment programs: A mixed methods analysis","volume":"141","author":"Hoffman","year":"2022","journal-title":"Journal of Substance Abuse Treatment"},{"author":"Hyndman","key":"10.1016\/j.josat.2024.209476_bb0075"},{"issue":"9","key":"10.1016\/j.josat.2024.209476_bb0080","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1001\/jamapsychiatry.2022.1776","article-title":"Methadone-involved overdose deaths in the US before and after federal policy changes expanding take-home methadone doses from opioid treatment programs","volume":"79","author":"Jones","year":"2022","journal-title":"JAMA Psychiatry"},{"issue":"7","key":"10.1016\/j.josat.2024.209476_bb0085","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.18223","article-title":"Methadone access for opioid use disorder during the COVID-19 pandemic within the United States and Canada","volume":"4","author":"Joudrey","year":"2021","journal-title":"JAMA Network Open"},{"issue":"11","key":"10.1016\/j.josat.2024.209476_bb0090","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/jamapsychiatry.2020.1511","article-title":"Methadone for opioid use disorder-decades of effectiveness but still miles away in the US","volume":"77","author":"Joudrey","year":"2020","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.josat.2024.209476_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.forsciint.2023.111579","article-title":"Examination of methadone involved overdoses during the COVID-19 pandemic","volume":"344","author":"Kaufman","year":"2023","journal-title":"Forensic Science International"},{"key":"10.1016\/j.josat.2024.209476_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109703","article-title":"Methadone-involved overdose deaths in the United States before and during the COVID-19 pandemic","volume":"242","author":"Kleinman","year":"2023","journal-title":"Drug and Alcohol Dependence"},{"issue":"4","key":"10.1016\/j.josat.2024.209476_bb0105","first-page":"6770","article-title":"Improving methadone access for rural communities in the USA: Lessons learned from COVID-19 adaptations and international models of care","volume":"21","author":"Lister","year":"2021","journal-title":"Rural and Remote Health"},{"key":"10.1016\/j.josat.2024.209476_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.109100","article-title":"Treatment provider perceptions of take-home methadone regulation before and during COVID-19","volume":"228","author":"Madden","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"author":"Medications for the Treatment of Opioid Use Disorder","key":"10.1016\/j.josat.2024.209476_bb0115"},{"year":"2021","series-title":"The impact of COVID-19 on outpatient visits in 2020: Visits remained stable, despite a late surge in cases","author":"Mehrotra","key":"10.1016\/j.josat.2024.209476_bb0120"},{"year":"2020","series-title":"85 Fed. Reg. 15337","author":"Proclamation No. 9994","key":"10.1016\/j.josat.2024.209476_bb0125"},{"key":"10.1016\/j.josat.2024.209476_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2021.103537","article-title":"Experiences with substance use disorder treatment during the COVID-19 pandemic: Findings from a multistate survey","volume":"101","author":"Saloner","year":"2022","journal-title":"The International Journal on Drug Policy"},{"year":"2020","series-title":"Opioid treatment program (OTP) guidance. March 19, 2020","author":"Substance Abuse and Mental Health Services Administration","key":"10.1016\/j.josat.2024.209476_bb0135"},{"author":"The R Foundation","key":"10.1016\/j.josat.2024.209476_bb0140"},{"issue":"3","key":"10.1016\/j.josat.2024.209476_bb0145","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2022.0093","article-title":"Trends in engagement with opioid use disorder treatment among Medicaid beneficiaries during the COVID-19 pandemic","volume":"3","author":"Tilhou","year":"2022","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.josat.2024.209476_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108514","article-title":"Perspectives of opioid use disorder treatment providers during COVID-19: Adapting to flexibilities and sustaining reforms","volume":"132","author":"Treitler","year":"2022","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"2","key":"10.1016\/j.josat.2024.209476_bb0155","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative effectiveness of different treatment pathways for opioid use disorder","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.josat.2024.209476_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2022.103591","article-title":"Methadone exposures reported to poison control centers in the United States following the COVID-19-related loosening of federal methadone regulations","volume":"102","author":"Welsh","year":"2022","journal-title":"International Journal of Drug Policy"}],"container-title":["Journal of Substance Use and Addiction Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875924001887?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875924001887?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,3]],"date-time":"2024-11-03T06:13:46Z","timestamp":1730614426000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949875924001887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":32,"alternative-id":["S2949875924001887"],"URL":"https:\/\/doi.org\/10.1016\/j.josat.2024.209476","relation":{},"ISSN":["2949-8759"],"issn-type":[{"type":"print","value":"2949-8759"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Methadone treatment utilization and overdose trends among Medicaid beneficiaries in New Jersey before and during the COVID-19 pandemic","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Use and Addiction Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.josat.2024.209476","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"209476"}}